Comparing the efficacy of different dexamethasone regimens for maintenance treatment of multiple myeloma in standard-risk patients non-eligible for transplantation

doi:10.12998/wjcc.v10.i32.11712

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 32

This Article

(161)

(171)

(0)

(8)

(2)

(4353)

(3)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Case Control Study

World J Clin Cases. Nov 16, 2022; 10(32): 11712-11725
Published online Nov 16, 2022. doi: 10.12998/wjcc.v10.i32.11712

Table 6 Comparison two groups with toxicity

Toxicity	DXM 40 mg group	DXM 20 mg group	P value
Adverse gastrointestinal reactions	14	6	0.044
GTA	3	5	0.426
IFG	4	7	0.303
DM	3	7	0.162
GTA + TFG + DM	10	19	0.033
β-CTX	5	12	0.049
Osteoporosis	5	7	0.487
Hypertension	4	5	0.677
TG	7	7	0.933
TC	8	9	0.717
Acne	3	6	0.267
PU	3	4	0.654
Insomnia	3	11	0.017

GTA: Glucose tolerance abnormal; IFG: Impaired fasting glucose; DM: Diabetes mellitus; β-CTX: β-crosslaps; TG: Triacylglycerol; TC: Total cholesterol; PU: Peptiu ulcer.

Full Size Table

Citation: Hu SL, Liu M, Zhang JY. Comparing the efficacy of different dexamethasone regimens for maintenance treatment of multiple myeloma in standard-risk patients non-eligible for transplantation. World J Clin Cases 2022; 10(32): 11712-11725
URL: https://www.wjgnet.com/2307-8960/full/v10/i32/11712.htm
DOI: https://dx.doi.org/10.12998/wjcc.v10.i32.11712

Hu SL, Liu M, Zhang JY. Comparing the efficacy of different dexamethasone regimens for maintenance treatment of multiple myeloma in standard-risk patients non-eligible for transplantation. World J Clin Cases 2022; 10(32): 11712-11725 [PMID: 36405288 DOI: 10.12998/wjcc.v10.i32.11712]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.